All In Biotech

Drug Trial Radar · NCT01706679

Evaluation of the Effect of ATX-101 on QT/QTc Intervals

A Four-Arm, Parallel Design, Randomized, Double-Blinded, Placebo and Active Controlled Study for the Evaluation of the Effect of Maximum Therapeutic and Supratherapeutic Single-Dose ATX-101 on the QT/QTc Intervals in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Nov 14, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 218 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

218

Actual

Start

Oct 2012

Primary completion

Feb 2013

Study completion Jun 2013

Sponsor

Lead sponsor
Kythera BiopharmaceuticalsIndustry
Sponsor type
Industry
First posted
Oct 15, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To evaluate the effect of maximum therapeutic and supratherapeutic doses of ATX-101 treatment on Fridericia's corrected QT interval (QTcF).

Conditions

  • Healthy

Interventions

  • ATX-101 (10 mg/ml)Drug

  • ATX-101 (20 mg/ml)Drug

  • Moxifloxacin (400 mg)Drug

  • Placebo vehicle (PBS)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The effect of maximum therapeutic and supratherapeutic doses of ATX-101 treatment on Fridericia's corrected QT interval (QTcF)Time frame: 2.5 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Comprehensive Clinical Development

    Miramar, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.